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Abstract 
Brain accumulation of amyloid‑beta (Aβ) is a crucial feature in Alzheimer´s disease (AD) and cerebral amyloid angi‑
opathy (CAA), although the pathophysiological relationship between these diseases remains unclear. Numerous 
proteins are associated with Aβ deposited in parenchymal plaques and/or cerebral vessels. We hypothesized that 
the study of these proteins would increase our understanding of the overlap and biological differences between 
these two pathologies and may yield new diagnostic tools and specific therapeutic targets. We used a laser capture 
microdissection approach combined with mass spectrometry in the APP23 transgenic mouse model of cerebral‑β‑
amyloidosis to specifically identify vascular Aβ‑associated proteins. We focused on one of the main proteins detected 
in the Aβ‑affected cerebrovasculature: MFG‑E8 (milk fat globule‑EGF factor 8), also known as lactadherin. We first 
validated the presence of MFG‑E8 in mouse and human brains. Immunofluorescence and immunoblotting studies 
revealed that MFG‑E8 brain levels were higher in APP23 mice than in WT mice. Furthermore, MFG‑E8 was strongly 
detected in Aβ‑positive vessels in human postmortem CAA brains, whereas MFG‑E8 was not present in parenchymal 
Aβ deposits. Levels of MFG‑E8 were additionally analysed in serum and cerebrospinal fluid (CSF) from patients diag‑
nosed with CAA, patients with AD and control subjects. Whereas no differences were found in MFG‑E8 serum levels 
between groups, MFG‑E8 concentration was significantly lower in the CSF of CAA patients compared to controls and 
AD patients. Finally, in human vascular smooth muscle cells MFG‑E8 was protective against the toxic effects of the 
treatment with the Aβ40 peptide containing the Dutch mutation. In summary, our study shows that MFG‑E8 is highly 
associated with CAA pathology and highlights MFG‑E8 as a new CSF biomarker that could potentially be used to dif‑
ferentiate cerebrovascular Aβ pathology from parenchymal Aβ deposition.
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Introduction
Cerebral β-amyloidosis is characterized by the accumu-
lation of amyloid-beta (Aβ) protein in the brain paren-
chyma and cerebral blood vessels, which are major 
features of Alzheimer’s disease (AD) and Aβ-associated 
cerebral amyloid angiopathy (CAA), respectively [1, 2]. 
AD is the main cause of dementia [3], whereas CAA is 
the most common cause of lobar intracerebral haemor-
rhage (ICH) in elderly individuals [4, 5]. The principal 
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neuropathological hallmarks of AD are the presence 
of neuritic plaques, initiated by the deposition of Aβ in 
the neuropil, and the intracellular generation of neu-
rofibrillary tangles (consisting of hyperphosphoryl-
ated tau protein) [6]. Conversely, CAA predominantly 
affects leptomeningeal and cortical arteries and arteri-
oles, although capillaries are also frequently involved [7]. 
Population-based autopsy studies have estimated a CAA 
prevalence of 20–40% in non-demented individuals and 
50–60% in those with dementia, which demonstrates its 
strong association with AD [8]. In fact, the prevalence of 
CAA pathology is particularly high in patients with AD, 
accounting for 47–100% of those patients [8].
Even though there is a large degree of overlap between 
the two pathologies, they are clinically distinct; whereas 
AD promotes neuronal loss and dementia, CAA leads to 
vascular dysfunction, lobar haemorrhage [9], and cogni-
tive decline independent of AD [10]. Moreover, although 
Aβ accumulates in both pathologies, the mechanisms 
explaining the different localization of the deposits in the 
brain have not been fully elucidated. Some factors seem 
to favor vascular or parenchymal Aβ deposition, such as 
the length of Aβ peptides; Aβ40 is predominantly found 
in CAA-affected vessels, whereas Aβ42 is the main com-
ponent of neuritic plaques in AD [11, 12]. In addition, 
mutations in the APP gene (β-amyloid precursor protein) 
can also predispose the formation and deposition of Aβ 
towards a vascular or a parenchymal location [13]. For 
instance, the E693Q mutation in APP causes the autoso-
mal dominant disorder Dutch-type hereditary CAA (also 
known as hereditary cerebral haemorrhage with amyloi-
dosis,  Dutch type, HCHWA-D), which is characterized 
by severe Aβ deposition in cerebral and cortical arteri-
oles with much less deposition in the brain parenchyma 
[9, 14]. On the other hand, a number of Aβ-associated 
proteins have been identified both in neuritic plaques 
and CAA, such as complement proteins, serum amyloid-
P component, glycosaminoglycans, and apolipoprotein 
E (ApoE) or apolipoprotein J (ApoJ) [13]. Recently, via 
proteomic analysis, the presence of ApoE or ApoJ was 
confirmed in leptomeningeal and cortical vessels from 
CAA patients [15–17]. In these studies, other proteins 
were identified being specifically associated with vascular 
deposits and absent from neuritic plaques, such as tissue 
inhibitor of metalloproteinases‐3 (TIMP3) [15], norrin 
(NDP), collagen-α-2(VI) (COL6A2) [16], or sushi repeat-
containing protein-1 (SRPX1) [18]. Whereas such a pro-
teomic strategy has been widely used in AD models [19, 
20], the identification of biomarkers related to vascular 
Aβ accumulation and their potential implications in the 
pathology have been less explored. Finding novel amy-
loid-associated proteins exclusively present in brain ves-
sels is still a challenge and may be a valid approach to find 
novel biomarkers for CAA and provide new insights into 
the mechanisms of CAA formation. For this purpose, we 
used a laser capture microdissection approach combined 
with proteomics to selectively isolate vascular or paren-
chymal Aβ deposits from a transgenic mouse model of 
cerebral β-amyloidosis. We focused our study on milk 
fat globule-EGF factor 8 (MFG-E8), as it was one of the 
proteins specifically detected with Aβ-affected cerebral 
vessels and absent from parenchymal Aβ plaques in the 
APP23 mouse model of AD/CAA. MFG-E8, also known 
as lactadherin, is a secreted glycoprotein originally iden-
tified as a component of milk fat globules with multifunc-
tional domains [21]. MFG-E8 accumulates within the 
arterial wall during aging and is abundantly expressed 
by vascular smooth muscle cells and other variety of cell 
types, including immune cells, astrocytes or microglia 
[22]. It has been reported to be involved in several physi-
ological and pathophysiological processes, including 
immunity [23], angiogenesis [24, 25], and the clearance of 
apoptotic cells [26, 27] and platelet-derived microvesicles 
from the circulation [28, 29]. Moreover, MFG-E8 plays a 
role in Aβ42 phagocytosis in vitro [30, 31], although its 
contributions to vascular dysfunction in AD and CAA 
still need to be established.
The first aim of this study was to validate the expression 
and localization of MFG-E8 protein in the APP23 trans-
genic model. We next explored the cerebral distribu-
tion of MFG-E8 in human postmortem cortical sections 
from CAA patients, where its association with vascular 
and parenchymal Aβ deposition was examined. Further-
more, circulating MFG-E8 levels were analysed in serum 
and cerebrospinal fluid (CSF) from CAA patients, AD 
patients and healthy controls. Finally, the contribution of 
MFG-E8 to Aβ-induced cytotoxicity in cultured human 
vascular smooth muscle cells was also investigated.
Material and methods
APP23 transgenic mice model
Mice were maintained on a 12-h/12-h light–dark 
cycle in a temperature-controlled room with food 
and water available ad  libitum. All animal procedures 
were approved by the Ethics Committee for Animal 
Experimentation of Vall d’Hebron Research Institute 
(78/13 CEEA) and were performed following Span-
ish legislation and in accordance with the Directives 
of the European Union. All experiments were car-
ried out on APP23 transgenic male mice (hemizygote 
B6, D2-TgN [Thy-APPSWE]-23-Tg mice, The Jackson 
Laboratory, Bar Harbor, ME, USA) [32]. These trans-
genic mice overexpress the human-type APP protein 
with the Swedish mutation (K670M/N671L) under the 
control of the murine brain and neuron-specific Thy-1 
promoter (thymocyte antigen-1). Hemizygous APP23 
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mice were backcrossed with C57BL/6 mice (Janvier 
Labs, Le Genest-Saint-Isle, France), and the APP gen-
otype was tested by Transnetyx (Cordova, TN, USA). 
Male wild-type (WT) and APP23 mice were aged in 
the Vall d’Hebron Research Institute animal facility 
to obtain the final study cohort at different age points 
(12, 18 and 24 months). The number of mice per group 
is specified in each figure.
Brain tissue preparation and laser capture microdissection
Paraffin-embedded brain tissue from 24-month-
old APP23 and WT mice (n = 3/ group) was cut into 
10  µm-thick sections and mounted onto ultravio-
let-irradiated 2  µm polyethylene naphthalate (PEN) 
membrane slides (MicroDissect GmbH, Herborn, 
Germany). Between 10 and 20 brain sections from 
each mouse were used to isolate an approximate total 
area of  106 µm2. An equivalent area of PEN membrane 
slices without brain tissue was also microdissected 
as negative control. Before microdissection, sec-
tions were deparaffinized for 1 h at 65  °C, rehydrated 
with graded ethanol solutions, and then stained with 
Thioflavin-S (ThS) (Sigma-Aldrich, Saint Louis, MO, 
USA) or tomato lectin (TL) (Lycopersicon esculentum 
lectin; Burlingame, Vector Labs, CA, USA) solution. 
ThS staining was performed to detect fibrillary Aβ 
(cerebral CAA vessels and parenchymal Aβ plaques) 
in APP23 mice. Briefly, sections were incubated in ThS 
(1% in 75% ethanol) for 30  s. The excess of ThS was 
removed, and the sections were then immersed in ThS 
(0.1% in 75% ethanol) for a minute. After washing with 
75% ethanol, samples were dehydrated and air-dried. 
In parallel, sections from 24-month-old WT mice were 
stained with TL to label all cerebral blood vessels and 
to be used as control material. These sections were 
rinsed twice in PBS-1% Tween 20 (PBST) for 5 min and 
then incubated with DyLight 594-labelled TL diluted 
1:100 in PBST for 1 h at room temperature (RT). Sec-
tions were finally washed with PBST, dehydrated, and 
air-dried. Laser capture microdissection (LCM) was 
performed using the 20 × objective of an LMD600 
microscope (Leica Microsystems, Wetzlar, Germany). 
ThS-positive vessels or parenchymal plaques from 
APP23 mice and TL-positive cerebral vessels from WT 
mice were independently collected into the caps of 
0.5 ml microcentrifuge tubes containing 20 μl of 1 mM 
EDTA (Sigma-Aldrich), 10  mM Tris (Sigma-Aldrich), 
0.002% Zwitterionic detergent (Sigma-Aldrich) and 
1/4 Protease Inhibitor Cocktail Tablet (Roche Diag-
nostic, Mannheim, Germany). The collected samples 
were frozen at − 80 °C until analysed.
Liquid chromatography‑mass spectrometry analysis 
and protein identification
Collected tissues were heated at 98  °C for 90  min and 
then sonicated for 60 min in a water bath refrigerated 
with ice. The samples were then digested with trypsin 
and subsequently analyzed using a linear ion trap 
Velos-Orbitrap mass spectrometer (Thermo Fisher, 
Bremen, Germany) by the Proteomics Unit of the Vall 
d’Hebron Institute of Oncology (VHIO, Barcelona, 
Spain). The peptide mixtures were fractionated by on-
line nanoflow liquid chromatography using an EASY-
nLC system (Proxeon Biosystems, Thermo Fisher) with 
a two-linear-column system. The LTQ Orbitrap Velos 
mass spectrometer was operated in the range of m/z 
300 to 1600 with a resolution of 30,000. The 20 most 
abundant ions were selected for fragmentation by col-
lision-induced dissociation with an isolation window of 
2 Da.
Proteins were identified using a MASCOT search 
(Matrix Science, London, UK) against the SwissProt 
database (version 2016_0108) taxonomy selected for 
Mus musculus (16,754 entries) or Homo sapiens (20,194 
entries). MS/MS spectra were searched with a precursor 
mass tolerance of 10 ppm, a fragment tolerance of 0.5 Da, 
and trypsin specificity with a maximum of two missed 
cleavages. The label-free approach was used for evalua-
tion based on the total number of spectra identified for a 
single protein, known as the spectral count. All proteins 
were sorted in descending order according to the spec-
tral count. The proteins identified in each group were 
considered present when they were detected in all three 
samples of each group with a spectral count ≥ 1. Shared 
proteins between experimental groups are also reported. 
All proteins identified for each experimental group are 
reported in Suppl. Data 1–7. The coverage of the murine 
MFG-E8 sequence and the peptides detected by mass 
spectrometry are shown in Additional file 1.
Mouse brain homogenates
The soluble protein fraction was obtained from each 
hemisphere of 12-, 18- and 24-month-old APP23 and 
WT mouse brain. Brain tissue was homogenized with 
a Dounce homogenizer in 4  ml of Tris-buffered saline 
(TBS; pH 7.4) containing a cocktail of protease inhibi-
tors (Roche). Each homogenate was then centrifuged at 
8000 × g for 30 min at 4 °C. The supernatant was selected 
as the soluble protein fraction. The collected fractions 
were frozen at − 80 °C until use. The protein concentra-
tion of each fraction was quantified with a BCA Protein 
Assay kit (Thermo Fisher) and was used for the validation 
of MFG-E8 in brains from WT and APP23 mice by west-
ern blot analysis.
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Immunofluorescence in mouse brain sections
Immunofluorescence validation of MFG-E8 expression 
was performed in paraffin-embedded brain sections from 
24-month-old APP23 and WT mice (n = 3/group). All 
samples were deparaffinized, hydrated, and treated with 
70% formic acid for antigen retrieval for 30  min. The 
samples were blocked in 3% bovine serum albumin (BSA; 
Sigma-Aldrich) in PBST for 1 h at RT and then incubated 
overnight (ON) with goat anti-MFG-E8 antibody (1:50, 
R&D Systems, Minneapolis, MN, USA). After rinsing, 
samples were incubated with the secondary antibody 
anti-goat-Alexa Fluor-488 (Thermo Fisher) diluted 1:500 
in blocking solution for 1 h at RT. Finally, samples were 
dehydrated, and 4′,6-diamidino-2-phenylindole (DAPI) 
was used for contrast staining before mounting the slices. 
MFG-E8-positive vessels were manually counted in each 
brain region under an Olympus BX61 microscope using 
a 10 ×  objective. Double immunofluorescence was per-
formed for MFG-E8 and Aβ using the same procedure 
as previously described. A mouse anti-Aβ monoclonal 
antibody (4G8, 1:1000, BioLegend, San Diego, CA, USA) 
was used as the primary antibody, and anti-mouse Alexa 
Fluor-568 (1:500, Thermo Fisher) was used as the second-
ary antibody. Double immunofluorescence images were 
captured with an Olympus FV1000 confocal microscope.
Immunohistochemistry in human brain tissue
Postmortem brain tissue was obtained from the Neu-
rological Tissue Bank of the Vall d’Hebron University 
Hospital (VHUH). The study was performed on 6 cases 
neuropathologically diagnosed with CAA and 6 con-
trols without CAA which were selected based on the 
absence of vascular amyloid pathology. Patients included 
in this study, or their relatives, expressed their willing-
ness to donate brain tissue for research purposes. The 
project was approved by the Clinical Investigation Ethi-
cal Committee of the Vall d’Hebron University Hospital, 
PR(IR)173/2019. All samples were obtained from 2 to 
20 h after death, and specimens were fixed in 10% buff-
ered formalin for 3–4  weeks. All patients included in 
the study had a complete autopsy that included a neu-
ropathological examination performed in the Pathology 
Department of the VHUH. Briefly, CAA lesions were 
graded following the criteria described by Greenberg 
and Vonsattel [33], and the classification into CAA type 
I and CAA type II was made according to the criteria 
described by Thal et al. [34]. AD neuropathologic change 
score was evaluated and staged according to the NIA-AA 
2012 criteria [35], combining Thal Aβ phases [34], Braak 
(neurofibrillary tangle scores) [36] and CERAD’s criteria 
(neuritic plaque scores) [37]. Cases were then classified 
according to the level of AD neuropathologic change 
score (low, intermediate or high) previously defined [35].
The presence of Aβ and MFG-E8 immunostaining was 
evaluated in consecutive sections of previously selected 
paraffin blocks. Paraffin-embedded cortical brain sec-
tions were deparaffinized, hydrated, and incubated with 
citrate buffer to improve antigen exposure (10  mM 
sodium citrate, 0.05% Tween 20, pH = 6) for 30  min 
at 95  °C. The sections were then blocked in 10% goat 
serum in PBST for 1  h at RT and incubated ON with 
the anti-Aβ monoclonal antibody 4G8 (1:5000, BioLe-
gend) or an anti-MFG-E8 polyclonal antibody (1:1000, 
Thermo Fisher). The slices were then treated with 3% 
hydrogen peroxide for 15  min to block endogenous 
peroxidases. Afterward, the slices were incubated with 
biotinylated anti-mouse IgG or anti-rabbit IgG (1:1000, 
Vector Labs) for 1  h at RT and then with streptavidin–
horseradish peroxidase (HRP; 1:1000, Vector Labs). 
Finally, diaminobenzidine (DAB; Dako, Denmark) was 
applied to the samples, and the sections were immersed 
in Harris haematoxylin solution (Sigma-Aldrich) for con-
trast staining. The samples were dehydrated, and DPX 
(Sigma-Aldrich) was used as a mounting medium. A Pan-
noramic 250 scanner (3DHistech, Budapest, Hungary) 
was used with a 20 × objective to digitize the histologi-
cal slides, and images were captured using Case Viewer 
Software (3DHistech). The immunodetection of Aβ and 
MFG-E8 in parenchymal plaques and cortical vessels was 
evaluated qualitatively according to the total number 
of deposits in an equivalent area of 385–400  mm2 in all 
the slides and was classified as follows: a score of 0 was 
assigned when no signal was detected (absence of depos-
its), a score of 1 was assigned for mild detection (1–50 
deposits), a score of 2 was assigned for moderate detec-
tion (51–100 deposits), and a score of 3 was assigned 
for intense detection (> 100 deposits). The evaluation of 
the slides and the determination of the score were con-
ducted by two investigators (P.M and E.M-S) blinded to 
the group distribution.
Serum MFG‑E8 determination
MFG-E8 levels were quantitatively determined by 
enzyme-linked immunosorbent assay (ELISA) in serum 
samples from CAA-associated ICH patients (n = 31), 
AD patients (n = 25), and age- and sex-matched controls 
(n = 39). All of them were recruited from the VHUH 
(Barcelona, Spain). The study was approved by the Clini-
cal Investigation Ethical Committee of the Vall d’Hebron 
University Hospital, Barcelona, Spain (PR(AG)326/2014) 
and was conducted in accordance with the Declaration of 
Helsinki. All patients provided signed informed consent 
before inclusion. Serum samples from CAA patients were 
collected in the non-acute phase (at least two months 
after the last ICH) to avoid the initial inflammatory pro-
cess. The CAA-ICH patients were > 55 years old and had 
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suffered lobar ICH with clinical suspicion of CAA diag-
nosed by magnetic resonance imaging (MRI) follow-
ing the modified Boston criteria [38]. The recruited AD 
patients presented sporadic probable AD according to 
the NIA-AA criteria [39]. The AD patients did not pre-
sent a history of stroke before recruitment. The control 
subjects were healthy family members or companions 
of the patients with no history of stroke or dementia. 
Peripheral blood was collected in EDTA tubes, and serum 
was immediately separated by centrifugation and stored 
at −80  °C. The final results were analysed following the 
manufacturer’s instructions (R&D Systems, #DFGE80) in 
a Synergy™ Mx Microplate reader (BioTek Instruments 
Inc., Winooski, VT, USA). Each serum sample (fivefold 
dilution) was assayed in duplicate.
Cerebrospinal fluid MFG‑E8 determination
MFG-E8 levels in cerebrospinal fluid (CSF) were meas-
ured in two independent clinical patient cohorts. AD 
patients (n = 26) and age- and sex-matched  controls 
(n = 10) were recruited from the VHUH (Barcelona, 
Spain). CAA patients (n = 23) and corresponding con-
trols (n = 27) were recruited from the Radboud Univer-
sity Medical Center (Nijmegen, The Netherlands). The 
use of CSF samples from patients and controls from both 
cohorts (VHUV and Radboud UMC) was approved by 
the local medical ethical committees and informed con-
sent was obtained from all study subjects or their legal 
representatives. CAA patients were diagnosed on the 
basis of the modified Boston Criteria [38], and were clas-
sified as either probable CAA (n = 18), CAA presenting 
with mixed-location cerebral hemorrhages (lobar and 
deep hemorrhages/microbleeds, n = 4)[38], or as con-
firmed suffering from a hereditary form of CAA, Heredi-
tary Cerebral Hemorrhage With Amyloidosis-Dutch type 
patients (n = 1). The recruited AD patients presented 
sporadic probable AD according to the NIA-AA cri-
teria [39] and did not present a history of stroke before 
recruitment. Control subjects underwent a lumbar punc-
ture as part of the diagnostic workup of neurologic symp-
toms or to exclude central nervous system involvement of 
a systemic disease. They neither had the suspected neu-
rological disease nor a neurodegenerative disease, known 
cognitive impairment, sepsis, stroke, nor a malignancy 
in the central nervous system (CNS). Additional inclu-
sion criteria were the availability of a sufficient amount 
of CSF and a normal composition of the CSF for a num-
ber of routine parameters. The levels of t-tau, p-tau and 
Aβ42 in the CSF of controls and patients were previously 
obtained. CSF Aβ40 concentrations were only available 
from Radboud UMC patients and controls. The CSF bio-
marker profile and demographic characteristics for both 
control cohorts are described in Additional file 2.
All CSF samples were obtained by lumbar puncture via 
standard procedures, collected in polypropylene tubes, 
centrifuged, and stored at -80 °C. Finally, the CSF MFG-
E8 levels were determined with a commercial ELISA kit 
(R&D Systems, #DFGE80) in tenfold diluted samples that 
were tested and analyzed in a blind manner to the diag-
nostic group.
Cell culture and treatments
Primary cultures of human brain vascular smooth muscle 
cells (HBVSMCs) were obtained from Innoprot (Derio, 
Bizkaia, Spain). The cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma-Aldrich) sup-
plemented with 10% fetal bovine serum (FBS; Gibco, 
MD, USA), 100 U/ml penicillin, and 100 μg/ml strepto-
mycin and maintained at 37  °C in a humidified incuba-
tor containing 5%  CO2. For treatments, cells were seeded 
on poly-L-lysine-coated 24- and 48-well cell culture 
plates at densities of 30,000 and 15,000 cells/ml, respec-
tively. The HBVSMCs were grown in DMEM complete 
serum medium for 48 h and starved in FBS-free DMEM 
medium for the treatments. Aβ(1–40) and Aβ(1–40) con-
taining the Dutch mutation (Aβ40-D; AnaSpec, San Jose, 
CA, USA) were dissolved in hexa-fluoro-2-isopropanol 
(Sigma-Aldrich) for 6 h and divided into 250 μg aliquots. 
The organic solvent was evaporated overnight, and ali-
quots were stored at −80 °C until use. To mimic the effect 
of Aβ in the cerebral vasculature, HBVSMCs were treated 
for 2 or 5 days with 25 μM Aβ(1–40) or 25 μM Aβ40-D 
previously resuspended in sterile water. Recombinant 
human MFG-E8 protein (rhMFG-E8; R&D Systems) was 
added at 2 µg/ml for 5 days.
MFG‑E8 knockdown by siRNA
HBVSMCs were seeded on poly-L-lysine-coated 48-well 
cell culture plates at a density of 15,000 cells/ml and were 
grown with DMEM complete serum medium for 48  h. 
A commercial Accell SMART pool of 4 short interfer-
ing RNAs (siRNAs, GE Dharmacon, Lafayette, CO, USA) 
was used to achieve MFG-E8 gene silencing. An Accell 
non-targeting siRNA pool (GE Dharmacon) was used as 
a negative control. The siRNAs were initially resuspended 
at 100 μM according to the manufacturer’s instructions. 
Cells were treated with 1 µM MFG-E8 siRNA or non-tar-
geting siRNA. Forty-eight hours after transfection, fresh 
FBS-free medium was added, and the cells were then 
treated with 25 μM Aβ40-D for 2 days.
Quantitative real‑time reverse transcriptase‑polymerase 
chain reaction (RT‑qPCR)
Total RNA was isolated from HBVSMCs using a Speed-
Tools Kit (Biotools, Madrid, Spain), and cDNAs were 
synthesized through reverse transcription using a 
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High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA) according to the man-
ufacturer’s instructions. The mRNA levels were quanti-
fied using TaqMan probes for MFG-E8 (Hs00983890_m1, 
Thermo Fisher) and PPIA (peptidylprolyl isomerase A, 
Hs99999904_m1, Thermo Fisher). Quantitative real-time 
reverse transcription PCR (RT-qPCR) was performed in 
triplicate using an Applied Biosystems Prism 7900HT 
Fast System. Gene expression was normalized to PPIA 
levels, and relative quantification values were calculated 
using the Livak Eq. (2-ΔΔCt).
Cell viability and total cell lysate preparation
The cytotoxicity in HBVSMCs was estimated by the 
mitochondrial-dependent reduction of 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; 
Sigma-Aldrich) to purple formazan. Briefly, after treat-
ments, cells were incubated with 0.5  mg/ml MTT solu-
tion for 90 min at 37 °C. The medium was replaced with 
dimethyl sulfoxide (Sigma-Aldrich) to dissolve formazan 
crystals, and the amount of formazan formed was spec-
trophotometrically quantified at 560  nm and 620  nm 
using a Synergy™ Mx Microplate reader (BioTek Instru-
ments Inc.). Cell viability is expressed as a percentage of 
the control condition for each independent experiment.
Total cell lysates for western blot analysis were obtained 
by cell collection in freshly prepared ice-cold lysis buffer 
containing 50  mM Tris–HCl, 150  mM NaCl, 5  mM 
 CaCl2, 0.05% BRIJ-35, 0.02%  NaN3, 1% Triton X-100, 1% 
phenylmethanesulfonyl fluoride (Sigma-Aldrich), and 
0.5% aprotinin (Sigma-Aldrich). The lysates were soni-
cated for 10 s and stored at -80 °C until use.
Immunocytochemistry
HBVSMCs were grown on poly-L-lysine-coated glass 
coverslips at a density of 15,000 cells/ml for 2 days. The 
cells were fixed for 15  min with 4% paraformaldehyde 
and blocked with 3% BSA in PBST for 1  h at RT. The 
slices were then incubated overnight with the following 
primary antibodies diluted in blocking solution: rab-
bit anti-MFG-E8 (1:50, Thermo Fisher) and mouse anti-
smooth muscle actin (1:100, SMA; Abcam, Cambridge, 
UK). After rinsing, the cells were incubated with second-
ary antibodies conjugated to Alexa Fluor 568 or Alexa 
Fluor 488 (Thermo Fisher) at a 1:500 dilution for 1 h at 
RT. Coverslips were finally mounted onto the glass slides 
using DAPI for nuceli staining. Images were acquired 
using a Zeiss LSM 980 confocal laser microscope.
Western blot
The protein concentrations in cell lysates were deter-
mined using a Pierce BCA protein assay kit (Thermo 
Scientific). Equal amounts of protein from mouse 
membrane-bound brain fractions (50  μg) or cell lysates 
(10 μg) were analysed by 10% SDS-PAGE and transferred 
onto a nitrocellulose membrane using a Trans-Blot Turbo 
transfer system (Bio-Rad, Hercules, CA, USA). The 
membranes were blocked for 1 h with 10% non-fat milk 
in PBST, and the membranes were then incubated with 
specific primary antibodies at 4 °C ON. After rinsing, the 
membranes were incubated with HRP-labelled secondary 
antibodies for 1 h at RT. Finally, the protein bands were 
visualized by enhanced chemiluminescence using Pierce® 
ECL Western Blotting Luminol (Thermo Fisher). ImageJ 
software was used to quantify the intensity of specific 
bands. All protein measurements were divided by β-actin 
measurements for normalization. The primary antibod-
ies used were goat anti-MFG-E8 (1:1000, R&D), rabbit 
anti-hMFG-E8 (1:1000, Thermo Fisher), and mouse anti-
β-actin (1:10,000, Sigma-Aldrich). The following HRP-
labelled secondary antibodies were used: anti-rabbit-HRP 
(1:2000, GE Healthcare Biosciences, Little Chalfont, UK), 
anti-mouse-HRP (1:2000, GE Healthcare Bioscience), 
and anti-goat-HRP (1:5000, GE Healthcare Bioscience).
Statistical analyses
The SPSS 20.0 package (IBM Corporation, Armonk, 
NY, USA) and GraphPad Prism 6 (GraphPad Software, 
La Jolla, CA, USA) were used for statistical analysis. 
For experimental results, the Shapiro–Wilk test was 
used to analyse the normality of continuous variables. 
In animal experiments, significant differences between 
groups were determined by Student’s t-test. The effects 
of genotype (G) and age (A) were evaluated by two-way 
analysis of variance (ANOVA) with Bonferroni’s post 
hoc test. In human cell culture experiments, differences 
between groups were determined by one-way ANOVA 
with Tukey’s post hoc test for multiple comparisons. In 
studies based on human samples, descriptive statistics 
were used to define demographic data and clinical char-
acteristics for the diagnostic groups (CAA patients and/
or AD patients and controls). Contingency tables were 
constructed and chi-squared tests were conducted for 
categorical variables. The distributions of continuous 
variables were tested using the Shapiro–Wilk or Kolmog-
orov–Smirnov test, as appropriate. For normally distrib-
uted variables, one-way ANOVA with Tukey’s post hoc 
test was performed. For non-normally distributed varia-
bles, the Mann–Whitney U-test was used for one-to-one 
comparisons, and the Kruskal–Wallis test with Dunn’s 
post hoc test was used for multiple comparisons. Asso-
ciations between two continuous variables were calcu-
lated with Spearman’s rho. The data are expressed as the 
mean ± SEM for normal distributions or as the median 
(interquartile range) for non-normal distributions. A 
Page 7 of 17Marazuela et al. acta neuropathol commun           (2021) 9:154  
p-value < 0.05 was considered to indicate statistical 
significance.
Results
Protein identification in the Aβ‑affected cerebral 
vasculature
To identify proteins that specifically co-deposited with 
Aβ in the cerebrovasculature, we used LCM followed by 
mass spectrometry in consecutive paraffin-embedded 
brain sections from 24-month-old APP23 and WT trans-
genic mice (Fig.  1A). Amyloid plaques and Aβ-positive 
vessels were detected using ThS staining in APP23 brains 
and were independently microdissected, as shown in 
Fig.  1B. Cerebral blood vessels from WT mice were 
visualized using TL staining and were selected as con-
trol material for LCM isolation (Fig. 1B, III). The proteins 
identified in each group are described in Additional file 3. 
A total of 194 proteins associated with parenchymal Aβ 
deposits were identified in APP23 mice (Fig. 1C). Among 
them, 89 proteins were exclusively found in plaques, 
including well-known amyloid-associated proteins such 
as ApoE, ApoJ, and GFAP (Additional file  3). On the 
other hand, 70 proteins were found to be associated 
with Aβ-positive vessels. However, after exclusion of the 
proteins identified in parenchymal plaques from APP23 
brains and in brain vessels from WT mice, the only pro-
teins exclusively detected in the Aβ-affected cerebral vas-
culature were MFG-E8 and TIMP3 (Additional file  3). 
Fig. 1 Study workflow for the identification of Aβ‑associated proteins. a Schematic representation of the LCM proteomic approach for tissue 
collection, microdissection, data analysis, and protein identification. b Representative brain sections from 24‑month‑old APP23 and WT mice 
before and after LCM. I) Aβ plaques from APP23 brains stained with thioflavin S (ThS). II) Aβ‑positive vessels from APP23 brains stained with ThS. III) 
Brain vessels from WT mice stained with tomato lectin (TL). The scale bar indicates 100 μm. c Venn diagram showing the total number of proteins 
identified in the three experimental groups
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Because TIMP3 in cerebral vessels from CAA patients 
has previously been described [15], we focused our study 
on the other candidate, MFG-E8.
MFG‑E8 expression in brain tissue from APP23 transgenic 
mice
To confirm the proteomic data, immunoblotting was 
performed on brain homogenates from 12- to 24-month-
old mice. MFG-E8 brain levels were significantly higher 
in 18- and 24-month-old APP23 mice than in age-
matched WT mice. Although MFG-E8 levels were 
strongly associated with genotype, an effect of age was 
also observed, only in APP23 mice (Fig. 2A). The plasma 
levels of MFG-E8 were also determined, although no 
significant differences between genotypes were found in 
24-month-old mice (Fig. 2A). We next evaluated the dis-
tribution of MFG-E8 in the mouse brain by immunofluo-
rescence staining. MFG-E8 was detected in brain vessels 
from both genotypes, but the number of MFG-E8-posi-
tive vessels was significantly higher in APP23 brains than 
in WT brains (Fig.  2B). Moreover, double immunofluo-
rescence showed that MFG-E8 was detected principally 
Fig. 2 MFG‑E8 expression analysis in APP23 mice. a Representative western blot images and quantification of MFG‑E8 protein levels in brain 
homogenates from 12‑, 18‑, and 24‑month‑old WT and APP23 mice and in 24‑month‑old plasma samples, n = 3–6/group. b Representative 
immunofluorescence images and quantification of the MFG‑E8‑positive vessels in brains from 24‑month‑old WT and APP23 mice. The scale bar 
indicates 100 μm, n = 3/group. c Representative confocal images showing the localization of MFG‑E8 (green) and Aβ (red) in parenchymal brain 
sections (I) from 24‑month‑old APP23 mice. II) Representative images showing no MFG‑E8 detection in parenchymal Aβ deposits. III) Representative 
images showing MFG‑E8 detection in an Aβ‑positive vessel. The scale bar indicates 10 μm. *p < 0.05, **p < 0.01, ****p < 0.0001
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in Aβ-positive vessels, and it was absent from Aβ plaques 
(Fig. 2C).
MFG‑E8 distribution in Aβ‑positive cortical brain vessels 
from human CAA brains
Next, the expression of MFG-E8 in human postmortem 
cortical brain sections was analysed in patients diagnosed 
with pathological CAA and in a control cohort. The 
principal demographic characteristics, neuropathologi-
cal features, and cause of death of all the cases included 
in the study are described in Additional file  4. Interest-
ingly, strong MFG-E8 staining was detected only in cor-
tical Aβ-positive vessels, as visualized in consecutive 
brain sections stained with anti-Aβ and anti-MFG-E8 in 
CAA cases (Fig. 3A). In fact, we confirmed the previous 
results found in APP23 mice in which MFG-E8 detec-
tion was restricted to vascular Aβ pathology, while Aβ 
parenchymal plaques did not show any immunoreactivity 
for MFG-E8. Control cases also showed some MFG-E8 
immunoreactivity, although the staining was less pro-
nounced in the brain parenchyma (Fig.  3A) and mostly 
restricted to leptomeningeal vessels.
The presence of MFG-E8 and Aβ in occipital brain sec-
tions was then evaluated and scored in the total cohort 
through IHC. The distribution of MFG-E8-positive ves-
sels was significantly higher in CAA cases than in con-
trols. Indeed, the highest MFG-E8 score was given to 
66.6% of CAA cases (4/6), while the lowest scores were 
given to non-CAA cases (p = 0.018) (Fig. 3B, I). Regard-
ing the distribution of MFG-E8 in Aβ-positive corti-
cal vessels, significant differences were found between 
groups (p = 0.014). As expected, MFG-E8 immunodetec-
tion was strongest in those groups with the highest cer-
ebrovascular Aβ scores; CAA cases with intense (1/1) 
Fig. 3 MFG‑E8 immunodetection in cortical brain sections from CAA patients and controls. a Representative images of brain Aβ and MFG‑E8 
presence in consecutive cortical brain sections from CAA patients or control individuals. b Distribution of MFG‑E8 staining according to (I) the 
presence or absence of CAA pathology and according to the (II) vascular and (III) parenchymal Aβ pathological burden. The graph shows the 
percentage of cases in each group. 0: No staining; 1: mild detection (1–50 positive deposits); 2: moderate detection (51–100); 3: intense detection 
(> 100 deposits) in the selected area for each section
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or moderate (3/3) vascular Aβ deposition presented a 
MFG-E8 score of 3, while cases without vascular Aβ 
involvement presented a MFG-E8 score of 1 (4/6) or 
2 (2/6) (Fig. 3B, II). On the other hand, CAA cases also 
presented an intense (4/6) or moderate (2/6) Aβ paren-
chymal deposition, however, the positivity of MFG-E8 
in brain vessels was not significantly associated with 
the number of Aβ plaques (p = 0.238) (Fig. 3B, III). It is 
important to remark that MFG-E8 presence was neither 
associated with neuritic plaques nor diffuse parenchymal 
deposits. Age was significantly different among groups 
(CAA cases: 82.3 ± 6.4 yrs; control cases: 74.5 ± 5 yrs; 
p = 0.04), but the MFG-E8 immunostaining score was not 
associated with age or any other neuropathological fea-
tures evaluated in the total cohort, including the Braak 
score or Vonsattel rating. MFG-E8 distribution was not 
associated with the AD neuropathological change score 
or the presence of ICH (Additional file 5).
Circulating MFG‑E8 levels
Circulating MFG-E8 levels were evaluated in serum 
samples from CAA-ICH patients (n = 31), AD patients 
(n = 25), and control participants (n = 39). However, 
no differences were found between groups (Additional 
file  6). Serum MFG-E8 levels were not associated with 
age, sex or other vascular risk factors (Additional file 7).
Circulating MFG-E8 levels were further evaluated in 
CSF samples from healthy controls, CAA patients, and 
AD patients obtained from two different clinical cohorts. 
Controls from Radboud UMC and from VHUH were 
pooled for posterior analysis (n = 37), as no significant 
differences were found regarding sex and age or lev-
els of CSF biomarkers (p-Tau, t-Tau and Aβ42) between 
cohorts (Additional file  2). Demographics and levels of 
CSF markers from all the groups included in the study are 
shown in Table  1. CAA patients presented significantly 
lower MFG-E8 levels in CSF (3345.5 (2661.8–4648.3) 
pg/ml) than AD patients (5655.6 (4552.6–6849.2) pg/ml; 
p < 0.001) and control subjects (4569.4 (3533.9–5848.7) 
pg/ml; p = 0.01) (Fig.  4A). Differences remained signifi-
cant after adjustment for age (CAA vs. controls: odds 
ratio (OR) 0.999 95% CI [0.999–1], p = 0.013; CAA vs. 
AD: OR 0.999 95% CI [0.999–1], p = 0.001). Next, the 
associations of MFG-E8 levels with other CSF biomark-
ers of the total cohort were evaluated. Interestingly, CSF 
MFG-E8 levels were positively correlated both with CSF 
Aβ40 (r = 0.502, p < 0.001) and Aβ42 levels (r = 0.395, 
p = 0.001) in the total cohort (Fig. 4B, C), suggesting that 
CSF MFG-E8 levels are dependent on Aβ levels. A weak 
correlation was also found between MFG-E8 levels and 
total tau levels in CSF (r = 0.236, p = 0.004). However, 
the concentration of the MFG-E8 protein in CSF was not 
associated with age (r = -0.121, p = 0.268) or CSF p-tau 
levels (r = 0.009, p = 0.932).
Modulation of MFG‑E8 expression by different Aβ‑40 
peptides in cultured HBVSMCs
Vascular smooth muscle cells are widely known to 
express MFG-E8 [40]. Double immunostaining of MFG-
E8 and SMA was performed to validate the in  vitro 
model used, and confirmed the expression of MFG-E8 
in HBVSMCs (Fig.  5A). The toxicity of two Aβ40 pep-
tides, Aβ40-wt and Aβ40-D, on cell viability was deter-
mined. Whereas no cytotoxicity was induced by Aβ40 in 
brain vascular cells cultured under the conditions tested, 
a significant decrease in cell viability was observed after 
5  days of treatment with the mutant Aβ40-D peptide 
(33.1% reduction vs control, p < 0.01) (Fig.  5B). Interest-
ingly, MFG-E8 protein levels were significantly increased 
only in HBVSMCs after 5 days of treatment with the toxic 
Aβ40-D peptide (83.3% increase vs control, p = 0.04), 
(Fig.  5C). However, no differences in MFG-E8 expres-
sion were shown after treatment with the nontoxic Aβ40 
peptide.
Table 1 Demographic characteristics and CSF parameters of healthy controls, CAA patients, and AD patients
CAA, Cerebral amyloid angiopathy; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; SD, standard deviation; IQR, interquartile range; -, not known. p-values below 0.05 are 
shown in bold: *p < 0.05 vs. the control group; **p < 0.01 vs. the control group; ***p < 0.001 vs. the control group; $p < 0.05 vs. the CAA group; $$$ p < 0.001 vs. the CAA group
Control (n = 37) CAA (n = 23) AD (n = 26) p‑Value
Demographics
Age, years, mean ± SD 63.8 ± 8.5 70.6 ± 7.8** 64.3 ± 7.3$ 0.004
Sex (female), n (%) 11 (29.7%) 7 (30.4%) 14 (53.8%) 0.110
CSF parameters, pg/ml
Aβ40, mean ± SD 10,187.9 ± 4009.1 7911.1 ± 3140.1 ‑ 0.032
Aβ42, median (IQR) 895.1 (678–1225) 360 (317.5–462)*** 514.6 (468.6–593.5)***  < 0.001
t‑Tau, median (IQR) 231 (170–317) 403 (268–512.5)** 328.6 (183.4–395.3) 0.002
p‑Tau, median (IQR) 28 (19–39) 45 (33.5–63.5)** 32.4 (18.1–39.6)$ 0.001
MFG‑E8, median (IQR) 4568.4 (3672.3–5898) 3345.5 (2661.8–4648.3)* 5655.6 (4552.6–6849.2)$$$  < 0.001
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Fig. 4 MFG‑E8 levels in CSF from controls, AD patients, and CAA patients. a Analysis of CSF MFG‑E8 levels in healthy controls (n = 37), AD patients 
(n = 26) and CAA patients (n = 23). b Correlation plot between CSF MFG‑E8 levels and CSF Aβ40 levels among controls and CAA patients (n = 50). 
c Correlation plot between CSF MFG‑E8 levels and CSF Aβ42 levels among controls, AD patients, and CAA patients (n = 86).*p < 0.05, ***p < 0.001. r, 
Spearman rho correlation coefficient
Fig. 5 MFG‑E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression 
of MFG‑E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40‑D 
peptide, n = 3–4/group. c Representative western blot images and quantification of MFG‑E8 protein levels after 2 and 5 days of treatment with 
25 μM Aβ40 peptide and the toxic Aβ40‑D peptide, n = 3–4/group. d Cell viability of HBVSMCs co‑treated with 2 µg/ml rhMFG‑E8 and 25 μM 
Aβ40‑D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40‑D for 48 h after transfection with MFG‑E8‑ or NT‑siRNA 
(n = 5/group). A non‑targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** 
p < 0.0001
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We next investigated whether exogenous administra-
tion of rhMFG-E8 was able to impact HBVSMC viability. 
Notably, no significant differences were found between 
non-treated cells and those treated with rhMFG-E8 
(Fig.  5D), indicating that MFG-E8 was not cytotoxic 
to HBVSMCs under the conditions tested. However, 
co-administration of rhMFG-E8 protein and Aβ40-D 
peptide significantly reduced the Aβ40-D-induced cyto-
toxicity in HBVSMCs compared to cells treated with 
Aβ40-D alone (38.3% reduction in toxicity vs cells treated 
with Aβ40-D, p = 0.007) (Fig. 5D). Finally, to further con-
firm that MFG-E8 could play a protective role in CAA 
pathology by attenuating Aβ40-D cytotoxicity, MFG-E8 
depletion was evaluated. HBVSMCs were treated with 
1  μM MFG-E8-specific siRNA for 48  h and then sub-
jected to 2  days of Aβ40-D treatment. The efficiency 
of MFG-E8 silencing was confirmed by RT-qPCR and 
western blot analyses 48 h post transfection (Additional 
file  8). Remarkably, MFG-E8 silencing exacerbated the 
slight Aβ40-D cytotoxicity observed at 2 days in HBVS-
MCs compared to that in non-transfected cells (14.1% 
increase in toxicity vs non-transfected cells treated with 
Aβ40-D, p < 0.001) (Fig. 5E).
Discussion
Interest in understanding the pathological interactions 
between AD and CAA has grown considerably in recent 
years. The discovery of new markers related to cerebral 
Aβ deposition is crucial for a better comprehension of 
the underlying pathological mechanisms and could sup-
port the development of novel potential disease-modify-
ing therapies. In the present study, we used an approach 
combining LCM and proteomics to identify new pro-
teins specifically associated with vascular Aβ in a widely 
used transgenic mouse model of cerebral β-amyloidosis. 
Our proteomic data confirmed the presence of proteins 
already well known to be related to parenchymal and vas-
cular Aβ deposits, such as ApoJ and ApoE [17, 41–43]. 
Remarkably, we identified two proteins selectively asso-
ciated with cerebrovascular Aβ, TIMP3 and MFG-E8. 
We focused our study on the MFG-E8 candidate since 
TIMP3 has been previously described in vessels from 
CAA patients [15, 44]. Our proteomic results demon-
strated that the LCM approach using an experimental 
transgenic model was a reliable tool that successfully vali-
dated candidates previously identified in other studies on 
humans.
MFG-E8 is a multifunctional glycoprotein expressed by 
a wide variety of cells, including epithelial cells, vascular 
smooth muscle cells, dendritic cells, microglia and astro-
cytes [22]. It has previously been associated with several 
physiological and pathological functions in the CNS, 
including phagocytosis of apoptotic cells [23, 26, 45], 
anti-inflammation [46, 47], and tissue regeneration[25], 
among others. In this regard, it has been shown that 
MFG-E8 binds to the Aβ42 peptide and increases micro-
glial neuroprotective activity against oligomeric Aβ tox-
icity in  vitro, suggesting that MFG-E8 can facilitate the 
clearance of Aβ by glial cells [30, 31]. The beneficial role 
of this protein in cerebral ischaemia has been extensively 
studied in mice, in which the treatment with MFG-E8 
reduces the infarct volume and the expression of inflam-
matory cytokines [48, 49]. The anti-inflammatory and 
anti-apoptotic roles of MFG-E8 have also been described 
in MFG-E8-deficient mice with transient occlusion of 
the middle cerebral artery [50, 51] and in rat models of 
traumatic brain injury administered with rhMFG-E8 
[52]. Additionally, a recent study also revealed that intra-
cerebroventricular MFG-E8 administration after suba-
rachnoid haemorrhage induction in mice decreases brain 
oedema by attenuating inflammation [53]. However, to 
the best of our knowledge, this is the first time that the 
MFG-E8 protein has been associated with vascular Aβ in 
CAA pathology.
In the CAA/AD experimental model, using immu-
nofluorescence techniques, we detected an increased 
presence of MFG-E8 protein in Aβ-positive vessels 
from APP23 brains, while this protein was absent from 
parenchymal Aβ deposits, which supported the previ-
ous proteomic findings. Furthermore, we confirmed 
these results in human postmortem cortical brain tissues 
from CAA patients. Indeed, a strong association between 
MFG-E8 presence and Aβ-affected cortical vessels, but 
not the parenchymal Aβ burden, was observed. In fact, 
we found that MFG-E8 expression was not related to 
the neuropathologically assessed risk score for AD. A 
previous report using human postmortem brain samples 
showed that total mRNA MFG-E8 levels were decreased 
in AD brains compared to controls [30]. That study did 
not analyze gene expression in CAA brain samples and/
or did not describe the prevalence of CAA pathology in 
the AD patient cohort, which makes it non-comparable 
to our study. However, it should be noted that low MFG-
E8 protein expression in Aβ plaque-enriched areas was 
found, which would be in agreement with our results, 
in which no MFG-E8 immunoreactivity was detected in 
parenchymal Aβ deposits. On the other hand, the asso-
ciation of medin, a small fragment derived from MFG-
E8 cleavage, with AD and vascular dementia has been 
recently described; previous studies have reported higher 
levels of medin in the cerebral arterioles from AD and 
vascular dementia patients than in those from controls 
[54]. Medin is one of the most common forms of age-
ing-related amyloid and accumulates in the vasculature, 
presenting a strong affinity to elastin fibres [55]. Increas-
ing evidence suggests that medin may cause vascular 
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dysfunction in ageing arteries and could contribute to 
age-associated vascular decline [56–58], although little is 
known about its physiological or pathologic effects and 
the mechanism by which it is cleaved from MFG-E8. In 
this line, a direct link between MFG-E8 and ageing has 
also been demonstrated [59–61]. However, in our study, 
MFG-E8 was not associated with age in the human 
cohorts analysed. Nevertheless, we detected MFG-E8 
expression in specific vessels from healthy control sub-
jects and in WT mice, and a significant association was 
found between MFG-E8 brain levels and ageing in APP23 
mice when mice with a wide age range were included in 
the study. Taken together, the involvement of MFG-E8 
expression in vascular ageing under physiological and 
pathological conditions merits further investigation.
Our results showing specific MFG-E8 accumula-
tion in the Aβ-containing cerebral vessels raised ques-
tions regarding the cellular origin and the modulation 
of MFG-E8 protein expression. In this regard, because 
MFG-E8 was not detected in parenchymal deposits 
or expressed in microglia or other parenchymal cells, 
it is plausible to assume that the elevated presence of 
the protein could have resulted from its expression in 
cerebrovascular cells or from a peripheral source. To 
test this latter possibility, we analysed the circulating 
MFG-E8 levels in the serum of CAA patients. In fact, 
previous studies have described elevated circulating 
levels of MFG-E8 in patients with different inflamma-
tory diseases [62, 63] and have observed an association 
between elevated MFG-E8 serum levels and the pres-
ence of high-intensity cerebral lesions on MRI [64]. 
Thus, we hypothesized that serum MFG-E8 may be 
modified in CAA patients, in whom the high preva-
lence of white matter lesions is well described [2, 65]. 
However, no differences were found in serum levels in 
CAA patients compared to AD cases or controls. In 
contrast, in CSF samples, lower MFG-E8 levels were 
found in the CAA group than in both the AD and con-
trol group. Interestingly, the Aβ CSF biomarker pro-
files for the clinical patient cohorts used in our study 
are consistent with previously reported data [66–68]. 
CAA patients presented lower Aβ42 and Aβ40 levels 
than controls. Remarkably, we found a positive cor-
relation between MFG-E8 levels and Aβ40 and Aβ2 
levels in the CSF, demonstrating, again, the strong 
association of this protein with Aβ levels. It has been 
hypothesized that CSF biomarker levels may reflect 
neuropathological changes in the brain [69, 70]. In 
this sense, the decreased Aβ levels in the CSF of CAA 
and AD patients may indicate possible impairment of 
the clearance of the peptides, potentially through the 
perivascular drainage pathway, which could explain 
the altered deposition of Aβ in the brain [71]. Similarly, 
our results demonstrate that MFG-E8 protein strongly 
accumulates in the cerebral vasculature of CAA 
patients, which may explain the reduced MFG-E8 con-
centrations in the CSF of these patients. In contrast, as 
MFG-E8 is absent from parenchymal Aβ deposits, no 
differences were observed in the CSF levels of MFG-E8 
in AD patients. Further studies in independent cohorts 
prospectively recruited and provided with complete 
MRI data are needed to confirm whether measure-
ment of CSF MFG-E8 levels could be used to differen-
tiate cerebrovascular pathology from parenchymal Aβ 
deposition. Besides, future analysis may also elucidate 
whether CSF MFG-E8 levels could be combined with 
other biomarkers described in CSF for CAA, such as 
ApoD [72] or Aβ/p-Tau, to improve the accuracy of its 
diagnosis. Nevertheless, the biological overlap between 
CAA and AD pathologies involves an intrinsic limita-
tion to differentiate the cohorts of the study. Although 
AD patients and controls selected in our study did not 
present a history of ICH, the lack of neuroimaging data 
in those cohorts could have masked the presence of 
CAA-related radiological markers. To overcome this 
limitation and define a clear CAA phenotype in com-
parison to other potential degrees of CAA pathology, 
we selected only patients with at least one lobar ICH 
or that had been clinically diagnosed according to the 
Boston clinical-radiographic criteria [38].
To determine the possible functional implication of 
MFG-E8 in CAA pathology, we simulated the patho-
logical scenario by treating HBVSMCs with Aβ40, the 
most prominent peptide that accumulates in CAA, and 
Aβ40-D, the mutant form generated in HCHWA-D 
patients. Consistent with the findings of previous stud-
ies, only treatment with the Aβ40-D peptide induced a 
significant decrease in HBVSMC viability, confirming 
its highly toxic response [73, 74]. Several studies have 
shown that MFG-E8 is abundantly expressed in vascu-
lar smooth muscle cells [40, 55, 59]. In this regard, we 
found specific increases in MFG-E8 protein levels only 
after treatment with the toxic Aβ40-D peptide. Previous 
studies have shown that exogenous MFG-E8 significantly 
increases the expression of pro-inflammatory genes in 
vascular smooth muscle cells isolated from the thoracic 
aortas of aged mice [59]. However, under the conditions 
evaluated, cell viability was not altered after rhMFG-E8 
treatment in human brain vascular smooth muscle cells. 
Indeed, we found that rhMFG-E8 supplementation sig-
nificantly increased cell viability after Aβ40-D treatment 
and, complementarily, silencing of MFG-E8 increased 
Aβ40-D-induced toxicity. Altogether, these results sug-
gest that MFG-E8 could play a protective role in CAA 
pathology, potentially reducing the cytotoxicity of Aβ. 
Whether MFG-E8 participates in Aβ phagocytosis or 
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acts by attenuating the inflammation induced at the vas-
cular level and reducing neuronal apoptosis requires fur-
ther investigation.
In summary, this study covered different aspects of 
the relation of MFG-E8 with CAA pathology; we started 
with an experimental approach using a mouse transgenic 
model; then studied the levels of MFG-E8 in the brain, 
blood and CSF; and finally explored the effects of modu-
lating MFG-E8 expression in cultured human smooth 
muscle cells. Overall, we have demonstrated that data 
obtained with an LCM proteomics approach using an 
experimental model of β-amyloidosis can be success-
fully translated to human studies. Our results indicate 
that MFG-E8 is closely associated with CAA; MFG-E8 
levels are increased in cerebral Aβ-positive vessels but 
decreased in CSF from CAA patients. Finally, we have 
shown that MFG-E8 expression is increased in HBVS-
MCs by toxic Aβ variants, which may prevent the vascu-
lar damage induced by Aβ. The discovery of MFG-E8 as a 
specific novel marker for CAA opens up new opportuni-
ties to explore more accurate diagnostic tools and poten-
tial therapeutic approaches for CAA. Additional in vivo 
functional studies are required to elucidate the molecular 
pathways involved in the protective role of MFG-E8 in 
CAA pathology.
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